News Verily plans digital ophthalmology joint venture with Santen Verily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen.
News Oxford Biomedica signs ophthalmology R&D deal with Santen UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
Partner Content Partner Content Queen's University Belfast and Santen to Present Opening Key... Ophthalmic Drugs Conference London
Events Partner Content Ophthalmic Drugs - Europe's Leading Ophthalmic Conference Ophthalmic Drugs Conference
Partner Content Partner Content Boehringer Ingelheim, Novaliq, Santen, Shire, at Europe's Le... SMi’s Leading Ophthalmic Conference
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
